Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 10

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 10
---
 of the units sold by the Company in its U.S. initial public offering with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), began trading on Nasdaq under the symbols "MDCX" and "MDCXW", respectively. Effective on February 21, 2025, the Company's common shares were voluntarily delisted from the TSXV. The common shares continue to be listed on Nasdaq.

<div align='center'>3</div>

On August 29, 2025, the Company completed the acquisition of 98.6% of the issued and outstanding shares of Antev, a company incorporated under the laws of England and Wales. The acquisition was completed pursuant to a securities exchange agreement, as amended, dated June 29, 2025 by and between the Company, Antev and the securityholders of Antev (the "Definitive Agreement").

The Company's registered and head office is located at One First Canadian Place, 100 King Street West, Suite 3400, Toronto, Ontario M5X 1A4, Canada.

We lease U.S. office space in Conshohocken, Pennsylvania to operate the businesses of our U.S. subsidiaries, Medicus Pharma Inc. and SkinJect, Inc. We also lease office space in Weybridge, U.K. to operate the business of our subsidiary Antev.

Our website address is www.medicuspharma.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our securities.

Warrant Inducement Agreement

On July 14, 2025, we entered into a warrant inducement agreement with the Selling Shareholder (the "Warrant Inducement Agreement"), pursuant to which the Selling Shareholder agreed to exercise existing warrants to purchase up to 1,340,000 of the Company's common shares issued on March 10, 2025 with an exercise price of $2.80 per Common Share (the "Regulation A Warrants"), in consideration for receiving the Private Warrants. In accordance with the Warrant Inducement Agreement the Selling Shareholder exercised its Regulation A Warrants for cash, for gross proceeds of $3,752,000 to the Company. Pursuant to the Warrant Inducement Agreement, the registration statement of which this prospectus forms